There are 2789 resources available
570P - Retrospective analysis of PDL-1, LAG3, TIM3, OX40L and MSI status in gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Presenter: Fatih Gurler
Session: ePoster Display
571P - Real-life monocentric, retrospective study on efficacy and tolerability of lenvatinib (Len) in patients (pts) with advanced radioactive iodine–refractory differentiated thyroid cancer (rDTC)
Presenter: Stefania Zovato
Session: ePoster Display
572P - Potential impact of molecularly-selected treatment in patients with endocrine neoplasms at a tertiary university hospital
Presenter: Javier Pozas
Session: ePoster Display
573P - Panorama of genomic RET alterations (GA) in the major subtypes of thyroid carcinomas (TC)
Presenter: Daniel Bowles
Session: ePoster Display
574P - Clinical impact of the GAPP score and SDHB negativity in patients with pheochromocytoma/paraganglioma
Presenter: Akihiro Ohmoto
Session: ePoster Display
575TiP - Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914)
Presenter: Enrique Grande
Session: ePoster Display
581P - Patient (pt) reported pain in men with metastatic castration-resistant prostate cancer (mCRPC) receiving talazoparib (TALA): TALAPRO-1
Presenter: Fred Saad
Session: ePoster Display
539P - Interim results of a phase I study of M701, a recombinant anti-EpCAM and anti-CD3 bispecific antibody in EpCAM-positive cancer patients with malignant ascites
Presenter: Jianming Xu
Session: ePoster Display